Objective: To observe the effect of Pingweisan on blood lipid

blood glucose and hepatocyte nuclear factor-1β(HNF-1β/TCF2) expression in mice with glycolipid metabolism disorder induced by high-fat diet

in order to explore the possible molecular mechanism of Pingweisan in regulating glucose and lipid metabolism in mice. Method: A total of 40 specific pathogen free (SPF) C57BL/6J adult male mice were randomly divided into normal group (n=8) and model group (n=32)

which were respectively fed with normal diet and high-fat diet for 10 weeks. Since the 11th week

the model group was randomly divided into model group (n=8)

Pingweisan group (n=8)

metformin group (n=8) and simvastatin group (n=8). The Pingweisan group was given Pingweisan 6 000 mg·kg-1·d-1

the metformin group was given metformin 300 mg·kg-1·d-1

the simvastatin group was given simvastatin 2 mg·kg-1·d-1

and the normal group and model group were given the same volume of distilled water only; that is to say

each group was given by gavage 10 mL·kg-1·d-1 for 4 weeks. During feeding

body weight

abdominal circumference

blood lipids

blood glucose and insulin were continuously monitored. After the intervention

liver and kidney tissues were taken to detect the mRNA and protein expression of HNF-1β. Result: At the end of the 10th week

compared with the normal group

the weight

abdominal circumference

total cholesterol (TC)

triglyceride (TG)

low-density lipoprotein cholesterol (LDL-C)

high-density lipoprotein cholesterol (HDL-C) and fasting plasma glucose (FPG) of the model group increased (P<0.05)

while fasting insulin (FINS) decreased (P<0.05). After 4 weeks of treatment

compared with the normal group

the body weight

abdominal circumference

blood lipid and 4 hours of blood glucose of oral glucose tolerance test (OGTT) of the model group were significantly increased (P<0.01). Relative mRNA and protein expressions of FINS and HNF-1β were decreased (P<0.05). Compared with the model group

the weight

abdominal circumference

TC

TG

and OGTT 4 hours of blood glucose of the Pingweisan group were all decreased (P<0.05)

whereas the relative mRNA and protein expressions of FINS and HNF-1β were all increased (P<0.05). The body weight

abdominal circumference

TC

TG

LDL-C

OGTT 4 hours of blood glucose of the metformin group were all decreased (P<0.05)

and the relative mRNA and protein expressions of FINS and HNF-1β were all increased (P<0.05). The body weight

abdominal circumference and the blood lipid of the simvastatin group were significantly decreased (P<0.01)

and the relative mRNA and protein expressions of FINS and HNF-1β were increased (P<0.05). Conclusion: After 10 weeks of high-fat diet

a mouse model of glycolipid metabolism disorder can be established. Pingweisan can regulate the blood lipid and blood glucose levels by regulating the expression of HNF-1β.